Cargando…
Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses
Despite the widespread use of SARS-CoV-2–specific monoclonal antibody (mAb) therapy for the treatment of acute COVID-19, the impact of this therapy on the development of SARS-CoV-2–specific T cell responses has been unknown, resulting in uncertainty as to whether anti–SARS-CoV-2 mAb administration m...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869965/ https://www.ncbi.nlm.nih.gov/pubmed/36378539 http://dx.doi.org/10.1172/jci.insight.163471 |
_version_ | 1784876876750127104 |
---|---|
author | Ramirez, Sydney I. Grifoni, Alba Weiskopf, Daniela Parikh, Urvi M. Heaps, Amy Faraji, Farhoud Sieg, Scott F. Ritz, Justin Moser, Carlee Eron, Joseph J. Currier, Judith S. Klekotka, Paul Sette, Alessandro Wohl, David A. Daar, Eric S. Hughes, Michael D. Chew, Kara W. Smith, Davey M. Crotty, Shane |
author_facet | Ramirez, Sydney I. Grifoni, Alba Weiskopf, Daniela Parikh, Urvi M. Heaps, Amy Faraji, Farhoud Sieg, Scott F. Ritz, Justin Moser, Carlee Eron, Joseph J. Currier, Judith S. Klekotka, Paul Sette, Alessandro Wohl, David A. Daar, Eric S. Hughes, Michael D. Chew, Kara W. Smith, Davey M. Crotty, Shane |
author_sort | Ramirez, Sydney I. |
collection | PubMed |
description | Despite the widespread use of SARS-CoV-2–specific monoclonal antibody (mAb) therapy for the treatment of acute COVID-19, the impact of this therapy on the development of SARS-CoV-2–specific T cell responses has been unknown, resulting in uncertainty as to whether anti–SARS-CoV-2 mAb administration may result in failure to generate immune memory. Alternatively, it has been suggested that SARS-CoV-2–specific mAb may enhance adaptive immunity to SARS-CoV-2 via a “vaccinal effect.” Bamlanivimab (Eli Lilly and Company) is a recombinant human IgG1 that was granted FDA emergency use authorization for the treatment of mild to moderate COVID-19 in those at high risk for progression to severe disease. Here, we compared SARS-CoV-2–specific CD4(+) and CD8(+) T cell responses of 95 individuals from the ACTIV-2/A5401 clinical trial 28 days after treatment with bamlanivimab versus placebo. SARS-CoV-2–specific T cell responses were evaluated using activation-induced marker assays in conjunction with intracellular cytokine staining. We demonstrate that most individuals with acute COVID-19 developed SARS-CoV-2–specific T cell responses. Overall, our findings suggest that the quantity and quality of SARS-CoV-2–specific T cell memory were not diminished in individuals who received bamlanivimab for acute COVID-19. Receipt of bamlanivimab during acute COVID-19 neither diminished nor enhanced SARS-CoV-2–specific cellular immunity. |
format | Online Article Text |
id | pubmed-9869965 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-98699652023-02-06 Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses Ramirez, Sydney I. Grifoni, Alba Weiskopf, Daniela Parikh, Urvi M. Heaps, Amy Faraji, Farhoud Sieg, Scott F. Ritz, Justin Moser, Carlee Eron, Joseph J. Currier, Judith S. Klekotka, Paul Sette, Alessandro Wohl, David A. Daar, Eric S. Hughes, Michael D. Chew, Kara W. Smith, Davey M. Crotty, Shane JCI Insight Research Article Despite the widespread use of SARS-CoV-2–specific monoclonal antibody (mAb) therapy for the treatment of acute COVID-19, the impact of this therapy on the development of SARS-CoV-2–specific T cell responses has been unknown, resulting in uncertainty as to whether anti–SARS-CoV-2 mAb administration may result in failure to generate immune memory. Alternatively, it has been suggested that SARS-CoV-2–specific mAb may enhance adaptive immunity to SARS-CoV-2 via a “vaccinal effect.” Bamlanivimab (Eli Lilly and Company) is a recombinant human IgG1 that was granted FDA emergency use authorization for the treatment of mild to moderate COVID-19 in those at high risk for progression to severe disease. Here, we compared SARS-CoV-2–specific CD4(+) and CD8(+) T cell responses of 95 individuals from the ACTIV-2/A5401 clinical trial 28 days after treatment with bamlanivimab versus placebo. SARS-CoV-2–specific T cell responses were evaluated using activation-induced marker assays in conjunction with intracellular cytokine staining. We demonstrate that most individuals with acute COVID-19 developed SARS-CoV-2–specific T cell responses. Overall, our findings suggest that the quantity and quality of SARS-CoV-2–specific T cell memory were not diminished in individuals who received bamlanivimab for acute COVID-19. Receipt of bamlanivimab during acute COVID-19 neither diminished nor enhanced SARS-CoV-2–specific cellular immunity. American Society for Clinical Investigation 2022-12-22 /pmc/articles/PMC9869965/ /pubmed/36378539 http://dx.doi.org/10.1172/jci.insight.163471 Text en © 2022 Ramirez et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Ramirez, Sydney I. Grifoni, Alba Weiskopf, Daniela Parikh, Urvi M. Heaps, Amy Faraji, Farhoud Sieg, Scott F. Ritz, Justin Moser, Carlee Eron, Joseph J. Currier, Judith S. Klekotka, Paul Sette, Alessandro Wohl, David A. Daar, Eric S. Hughes, Michael D. Chew, Kara W. Smith, Davey M. Crotty, Shane Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses |
title | Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses |
title_full | Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses |
title_fullStr | Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses |
title_full_unstemmed | Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses |
title_short | Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses |
title_sort | bamlanivimab therapy for acute covid-19 does not blunt sars-cov-2–specific memory t cell responses |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869965/ https://www.ncbi.nlm.nih.gov/pubmed/36378539 http://dx.doi.org/10.1172/jci.insight.163471 |
work_keys_str_mv | AT ramirezsydneyi bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT grifonialba bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT weiskopfdaniela bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT parikhurvim bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT heapsamy bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT farajifarhoud bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT siegscottf bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT ritzjustin bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT mosercarlee bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT eronjosephj bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT currierjudiths bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT klekotkapaul bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT settealessandro bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT wohldavida bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT daarerics bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT hughesmichaeld bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT chewkaraw bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT smithdaveym bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT crottyshane bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses AT bamlanivimabtherapyforacutecovid19doesnotbluntsarscov2specificmemorytcellresponses |